Literature DB >> 16462750

Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes.

Ileana Ramazzina1, Claudia Folli, Andrea Secchi, Rodolfo Berni, Riccardo Percudani.   

Abstract

Mammals that degrade uric acid are not affected by gout or urate kidney stones. It is not fully understood how they convert uric acid into the much more soluble allantoin. Until recently, it had long been thought that urate oxidase was the only enzyme responsible for this conversion. However, detailed studies of the mechanism and regiochemistry of urate oxidation have called this assumption into question, suggesting the existence of other distinct enzymatic activities. Through phylogenetic genome comparison, we identify here two genes that share with urate oxidase a common history of loss or gain events. We show that the two proteins encoded by mouse genes catalyze two consecutive steps following urate oxidation to 5-hydroxyisourate (HIU): hydrolysis of HIU to give 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) and decarboxylation of OHCU to give S-(+)-allantoin. Urate oxidation produces racemic allantoin on a time scale of hours, whereas the full enzymatic complement produces dextrorotatory allantoin on a time scale of seconds. The use of these enzymes in association with urate oxidase could improve the therapy of hyperuricemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462750     DOI: 10.1038/nchembio768

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  73 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

2.  Peroxisome biogenesis and function.

Authors:  Navneet Kaur; Sigrun Reumann; Jianping Hu
Journal:  Arabidopsis Book       Date:  2009-09-11

3.  Substrate selectivity of YgfU, a uric acid transporter from Escherichia coli.

Authors:  Konstantinos Papakostas; Stathis Frillingos
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

Review 4.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

Authors:  Tuhina Neogi; Jacob George; Sushma Rekhraj; Allan D Struthers; Hyon Choi; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2012-02

Review 5.  Practical and theoretical advances in predicting the function of a protein by its phylogenetic distribution.

Authors:  Philip R Kensche; Vera van Noort; Bas E Dutilh; Martijn A Huynen
Journal:  J R Soc Interface       Date:  2008-02-06       Impact factor: 4.118

6.  Ureide catabolism in Arabidopsis thaliana and Escherichia coli.

Authors:  Andrea K Werner; Tina Romeis; Claus-Peter Witte
Journal:  Nat Chem Biol       Date:  2009-11-22       Impact factor: 15.040

7.  Evolutionary history and metabolic insights of ancient mammalian uricases.

Authors:  James T Kratzer; Miguel A Lanaspa; Michael N Murphy; Christina Cicerchi; Christina L Graves; Peter A Tipton; Eric A Ortlund; Richard J Johnson; Eric A Gaucher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

8.  Proteome analysis of Arabidopsis leaf peroxisomes reveals novel targeting peptides, metabolic pathways, and defense mechanisms.

Authors:  Sigrun Reumann; Lavanya Babujee; Changle Ma; Stephanie Wienkoop; Tanja Siemsen; Gerardo E Antonicelli; Nicolas Rasche; Franziska Lüder; Wolfram Weckwerth; Olaf Jahn
Journal:  Plant Cell       Date:  2007-10-19       Impact factor: 11.277

Review 9.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

10.  Functional characterization of Arabidopsis thaliana transthyretin-like protein.

Authors:  João Pessoa; Zsuzsa Sárkány; Frederico Ferreira-da-Silva; Sónia Martins; Maria R Almeida; Jianming Li; Ana M Damas
Journal:  BMC Plant Biol       Date:  2010-02-18       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.